Invega (Paliperidone)
Purpose of Medication and Method of Action
This newly approved drug is indicated for the treatment of schizophreia. Initial trials evaluated its effectiveness for only 6 weeks so therapy beyond that time is considered investigational. Invega is the active metabolite of resperidone and shares the parent drug’s pharmacology. The mechanism of action is tproposed to be mediated through a combination of central dopamine and serotonin receptor antagonism.
Side Effects
There is an increase in mortality in elderly patients with dementia-related psychosis.
Drug Interactions
Invega may produce an increase in QT interval and should not be used with other drugs which also product a similar EKG effect such as quinidine and amiodarone.
Patient Medication Information
These information sheets do not list all known side effects of the medications, only the most common side effects. For a complete list of side effects please contact your local pharmacy or the actual drug manufacturing company.